bms-986158
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 5, 2015 (NCT02419417)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Bromodomain-containing protein 7INHIBITOR
BRD7 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986158
- bms-986158
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05372354 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2022 | Bristol-Myers Squibb |
| NCT04817007 | Phase 1 | Mar 23, 2021 | Bristol-Myers Squibb |
| NCT03936465 | Phase 1 | Jun 30, 2019 | Harvard University, Stand Up To Cancer |
| NCT02419417 | Phase 1/Phase 2 (Phase 2) | Jun 5, 2015 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 2 | 2015 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1